Israeli regulations only began requiring GMP to be used for local medical cannabis in 2018. This has led to increasing investments required for different parts of the value chain, an increase in pricing, and as in other places, a lively, highly competitive black market that has been gaining strength from the legal medical market.
In Israel, cannabis products are an independent segment; they arrive as a finished product, with no intervention from pharmacists selling it under license.
Branding, colorful names and graphics are allowed, which further creates an overlap between medical cannabis and recreational forms of the product. It is very confusing, indeed.
Read the whole article on the GQC website